REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 1st, 2024 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances
This Agreement is made pursuant to the Investment Agreement, dated as of January 8, 2024, between the Company and the Investor (as amended, amended and restated or otherwise modified from time to time, the “Investment Agreement”), pursuant to which the Company is selling to the Investor, and the Investor is purchasing from the Company, in each case on the Closing Date (as defined in the Investment Agreement), an aggregate of 56,342,355 shares (the “Shares”) of common stock, $0.001 par value of the Company (the “Common Stock”).
LANTHEUS HOLDINGS, INC., as Issuer, LANTHEUS MEDICAL IMAGING, INC., as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 8, 2022 2.625% Convertible Senior Notes due 2027Indenture • December 8th, 2022 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
INDENTURE dated as of December 8, 2022 among LANTHEUS HOLDINGS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01), LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation and a wholly owned subsidiary of the Company, as guarantor (the “Guarantor,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
Lantheus Holdings, Inc. 5,200,000 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • September 13th, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Lantheus Holdings, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis), 5,200,000 shares of common stock, $0.01 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Pr
Lantheus Holdings, Inc. 3,000,000 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • March 15th, 2017 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Certain stockholders named in Schedule II hereto (the “Selling Stockholders”) of Lantheus Holdings, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), propose to sell to the several underwriters named in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis), the number of shares of Common Stock set forth in Schedule II hereto (said shares to be sold by the Selling Stockholders collectively being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before
Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT NO. 1 TO CREDIT AGREEMENT (this “Amendment”), dated as of June 19, 2020, among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (the “Borrower”), LANTHEUS HOLDINGS, INC., a...Credit Agreement • July 31st, 2020 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
AMENDED AND RESTATED CREDIT AGREEMENT among LANTHEUS MEDICAL IMAGING, INC., as Borrower, LANTHEUS HOLDINGS, INC., The Several Lenders from Time to Time Parties Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent and...Credit Agreement • May 2nd, 2017 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS, reference is made to the Term Loan Agreement, dated as of June 30, 2015 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time immediately prior to the date hereof, the “Original Credit Agreement”), by and among the Borrower, Holdings, the several lenders from time to time parties thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent (in such capacity, the “Original Administrative Agent”).
CREDIT AGREEMENT Dated as of December 2, 2022 among LANTHEUS MEDICAL IMAGING, INC., as Borrower, LANTHEUS HOLDINGS, INC., The several Lenders from time to time parties hereto, CITIZENS BANK, N.A., as Administrative Agent and Collateral Agent, CITIZENS...Credit Agreement • December 5th, 2022 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
CREDIT AGREEMENT, dated as of December 2, 2022, among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (the “Borrower”), LANTHEUS HOLDINGS, INC., a Delaware corporation (“Holdings”), the several banks and other financial institutions or entities from time to time parties hereto, as Lenders, and CITIZENS BANK, N.A. (“Citizens”), as administrative agent and collateral agent (in such capacities, and together with its successors and permitted assigns in such capacities, the “Administrative Agent” and the “Collateral Agent,” respectively) and the Issuing Lender (as defined below).
EMPLOYMENT AGREEMENTEmployment Agreement • May 3rd, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
EMPLOYMENT AGREEMENT (the “Agreement”) dated as of August , 2013 by and between Lantheus Medical Imaging, Inc., a Delaware corporation (the “Company”) and John Crowley (“Executive”).
Lantheus Holdings, Inc. Stock Option Award Agreement (Time Vesting)Stock Option Award Agreement • June 16th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Stock Option Award Agreement (this “Agreement”) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and [●] (the “Participant”), effective as of , 2015 (the “Date of Grant”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 3rd, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
This Amendment to Employment Agreement (“Amendment”) is entered into as of June , 2015, by and between John Crowley, an individual (“Employee”), and Lantheus Medical Imagining, Inc., a Delaware corporation (the “Company”).
Lantheus Holdings, Inc. 3,000,000 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • June 16th, 2017 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Certain stockholders named in Schedule II hereto (the “Selling Stockholders”) of Lantheus Holdings, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), propose to sell to the several underwriters named in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis), the number of shares of Common Stock set forth in Schedule II hereto (said shares to be sold by the Selling Stockholders collectively being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before
Lantheus Holdings, Inc. Restricted Stock Award Agreement (Time Vesting)Restricted Stock Award Agreement • June 16th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Restricted Stock Award Agreement (this “Agreement”) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and [●] (the “Participant”), effective as of June [●], 2015 (the “Date of Grant”).
Lantheus Holdings, Inc. [ — ] Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • June 24th, 2014 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Lantheus Holdings, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ — ] shares of common stock, $0.01 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ — ] additional shares of Common Stock solely to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural
LANTHEUS HOLDINGS, INC. Restricted Stock AgreementRestricted Stock Agreement • June 8th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AGREEMENT (the “Agreement”) is made between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and _________ (the “Participant”), effective _________ (the “Effective Date”).
AMENDED AND RESTATED ASSET PURCHASE AGREEMENT January 13, 2016Asset Purchase Agreement • August 25th, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
This AMENDED AND RESTATED ASSET PURCHASE AGREEMENT is made by and between (i) Lantheus MI Canada, Inc., a Canadian corporation (“Seller”), on the one hand, and (ii) Isologic Innovative Radiopharmaceuticals Ltd., a Canadian corporation (“Buyer”), on the other hand, amends and restates in its entirety the original Asset Purchase Agreement by and between Seller and Buyer executed as of December 31, 2015 (the “Execution Date”) and made effective only as of January 7, 2016 (this “Agreement”).
AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 20, 2020Agreement and Plan of Merger • February 20th, 2020 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Amended and Restated Agreement and Plan of Merger (this “Agreement”), dated as of February 20, 2020 (the “Execution Date”), among Lantheus Holdings, Inc., a Delaware corporation (“Parent”), Plato Merger Sub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), amends and restates in its entirety that certain Agreement and Plan of Merger (the “Original Merger Agreement”), dated as of October 1, 2019 (the “Original Execution Date”), among Parent, Merger Sub and the Company. Parent, Merger Sub and the Company are referred to individually as a “Party” and collectively as the “Parties”. Capitalized terms have the meanings given to them in Section 1.1.
AMENDMENT NUMBER ONE TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • July 9th, 2014 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT NUMBER ONE TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of June 24, 2014, is entered into by and among LANTHEUS MI INTERMEDIATE, INC., a Delaware corporation (the “Parent”), LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (the “Borrower”), the lenders identified on the signature pages hereof (such lenders, and the other lenders party to the below-defined Credit Agreement, together with their respective successors and permitted assigns, each individually, a “Lender”, and collectively, the “Lenders”), each subsidiary of the Parent listed as a “Guarantor” on the signature pages hereto (together with the Parent, each a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”; Borrower and Guarantors, each a “Loan Party” and individually and collectively, jointly and severally, the “Loan Parties”), and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, in its capacity as collateral agent for th
LANTHEUS HOLDINGS, INC. Stock Option Agreement – Time VestingStock Option Agreement • June 8th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AGREEMENT (the “Agreement”) is made effective as of _________ (the “Date of Grant”) by and between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and _________ (the “Participant”).
Contingent Value Rights Agreement between Lantheus Holdings, Inc. and Computershare Inc. Computershare Trust Company, N.A. collectively, as Rights Agent Dated as of June 19, 2020Contingent Value Rights Agreement • June 22nd, 2020 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of June 19, 2020 (this “Agreement”), is entered into by and between Lantheus Holdings, Inc., a Delaware corporation (“Lantheus”), and Computershare, Inc. (“Computershare”), a Delaware corporation, and its wholly owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (collectively, the “Rights Agent”).
AFFIRMATION AND ASSUMPTION AGREEMENTAffirmation and Assumption Agreement • June 30th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances
This Affirmation and Assumption Agreement (this “Assumption Agreement”) is made as of June 25, 2015, by LANTHEUS HOLDINGS, INC., a Delaware corporation (“Target”), in favor of WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, in its capacity as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, if any, the “Collateral Agent”) and as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, if any, the “Administrative Agent”), and the Lenders, with reference to the following facts:
AMENDMENT TO THE AMENDED AND RESTATED SHAREHOLDERS AGREEMENT June 25, 2015Shareholders Agreement • June 30th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS, the undersigned parties to this amendment (this “Amendment”) are parties to that certain Amended and Restated Shareholders Agreement, dated as of February 26, 2008 (as may be amended from time to time the “Agreement”), among (i) Lantheus Holdings, Inc. (f/k/a Lantheus MI Holdings, Inc.), a Delaware corporation (the “Company”), (ii) Avista Capital Partners, L.P., a Delaware limited partnership, Avista Capital Partners (Offshore), L.P., a Delaware limited partnership, and ACP Lantern Co-Invest, LLC, a Delaware limited liability company (each of the foregoing in this clause (ii), an “Avista Entity” and, collectively, the “Avista Entities”), and (iii) each person listed as a “Management Shareholder” on the signature pages thereto or that has subsequently become a party to the Agreement as a “Management Shareholder” (each a “Management Shareholder” and, collectively, the “Management Shareholders”);
CONSULTING AGREEMENTConsulting Agreement • April 1st, 2021 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Consulting Agreement is made by and between Lantheus Medical Imaging, Inc. (the “Company”) and Michael P. Duffy (“you”) (each of the Company and you, individually, a “Party” and, collectively, the “Parties”), as of March 31, 2021 (the “Effective Date”) (this “Agreement”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “***”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND...Supply Agreement • August 1st, 2017 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AMENDED AND RESTATED SUPPLY AGREEMENT (this “Agreement”) is entered into as of April 25, 2017 (the “Effective Date”) by and between MEDI-PHYSICS INC., a Delaware corporation doing business as “GE Healthcare,” having a place of business at 100 Results Way, Marlborough, MA 01752, United States of America (“GE Healthcare”) and LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation having its principal place of business at 331 Treble Cove Road, North Billerica, MA 01862, United States of America (“LMI”). GE Healthcare and LMI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment No. 3 to Sales AgreementSales Agreement • May 2nd, 2018 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • England
THIS AMENDMENT NO. 3 TO SALES AGREEMENT (this “Amendment”) is made effective as of October 1, 2012 by and between NTP Radioisotopes (Pty) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, Church Street West Extension, Brits District, North West Province of South Africa (“NTP”), and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 (“Lantheus”).
ContractOffice Lease • August 3rd, 2023 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
Certain identified information has been omitted from this exhibit because it is (i) not material and (ii) of the type that the registrant treats as private or confidential. [***] indicates the information has been omitted.
SUPPORT AGREEMENTSupport Agreement • April 14th, 2020 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This SUPPORT AGREEMENT, dated as of April 14, 2020 (this “Agreement”), is entered into by and between Lantheus Holdings, Inc., a corporation existing under the laws of Delaware (“Parent”), and the parties listed on Schedule A and Schedule B attached hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Unless otherwise indicated, capitalized terms not defined herein have the meanings given to them in the Merger Agreement (as defined below).
Amendment No. 2 to Sales AgreementSales Agreement • May 2nd, 2018 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 2 TO SALES AGREEMENT (this “Amendment”) is made effective as of April 1, 2011 by and between NTP Radioisotopes (Pty) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, Church Street West Extension, Brits District, North West Province of South Africa (“NTP”), and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 (“Lantheus”).
AMENDMENT TO THE EMPLOYEE SHAREHOLDERS AGREEMENT Dated June 25, 2015Employee Shareholders Agreement • June 30th, 2015 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS, the undersigned parties to this amendment (this “Amendment”) are parties to that certain Employee Shareholders Agreement, dated as of May 8, 2008 (as may be amended from time to time, the “Agreement”), among (i) Lantheus Holdings, Inc. (f/k/a Lantheus MI Holdings, Inc.), a Delaware corporation (the “Company”), (ii) Avista Capital Partners, L.P., a Delaware limited partnership, Avista Capital Partners (Offshore), L.P., a Delaware limited partnership, and ACP Lantern Co-Invest, LLC, a Delaware limited liability company (each of the foregoing in this clause (ii), an “Avista Entity” and, collectively, the “Avista Entities”), and (iii) each person listed as an “Employee Shareholder” on the signature pages thereto or that has subsequently become a party to the Agreement as an “Employee Shareholder” (each an “Employee Shareholder” and, collectively, the “Employee Shareholders”);
Amendment No. 4 to Sales AgreementSales Agreement • February 26th, 2018 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances
This Amendment No. 4 to Sales Agreement (this “Amendment”) is made by and between (i) NTP Radioisotopes (SOC) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, R104 Elias Motswaledi Extension, Brits District, North West Province of South Africa (“NTP”), and (ii) Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 (“Lantheus”), effective as of December 29, 2017 (the “Amendment Effective Date”).
AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF OCTOBER 1, 2019Merger Agreement • October 2nd, 2019 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Agreement and Plan of Merger, dated as of October 1, 2019 (this “Agreement”), is made and entered into among Lantheus Holdings, Inc., a Delaware corporation (“Parent”), Plato Merger Sub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Parent, Merger Sub and the Company are referred to individually as a “Party” and collectively as the “Parties”. Capitalized terms have the meanings given to them in Section 1.1.
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “***”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. SECOND AMENDMENT...Manufacturing and Supply Agreement • November 1st, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
This Second Amendment to Manufacturing and Supply Agreement (this “Amendment”), dated as of September 2, 2016 (the “Amendment Effective Date”), is hereby entered into by and between Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 331 Treble Cove Road, North Billerica, MA 01862 (“LMI”), and Jubilant HollisterStier LLC, a limited liability company organized and existing under the laws of Delaware with a place of business at 3525 North Regal Street, Spokane, Washington, 99207 (“HSL”). LMI and HSL are referred to herein individually as a “Party” and collectively as the “Parties.”
August 20, 2018 VIA HAND DELIVERY Jack Crowley c/o Lantheus Medical Imaging, Inc. North Billerica, MA 01862 Dear Jack:Separation Agreement • October 30th, 2018 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This letter agreement (this “Agreement”) confirms the terms of your separation from Lantheus Medical Imaging, Inc. (the “Company”), effective as of August 20, 2018 (the “Separation Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 20th, 2019 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
EMPLOYMENT AGREEMENT (the "Agreement") dated as of November 22, 2013 by and between Lantheus Medical Imaging, Inc., a Delaware corporation (the "Company") and Michael Duffy ("Executive").
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “***”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. SHARE PURCHASE...Share Purchase Agreement • November 1st, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
This SHARE PURCHASE AGREEMENT is made by and between Lantheus Medical Imaging, Inc., a Delaware corporation (“Seller”) and Global Medical Solutions, Ltd., a company incorporated under the laws of the Cayman Islands or (with Seller’s prior approval, not to be unreasonably withheld) its Affiliated designee (“Buyer”), as of the date first written above (the “Effective Date”) (this “Agreement”).
CONSULTING AGREEMENTConsulting Agreement • July 31st, 2024 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Consulting Agreement is made by and between Lantheus Medical Imaging, Inc. (together with its affiliates, the “Company”) and Etienne Montagut (“you”) (each of the Company and you, individually, a “Party” and, collectively, the “Parties”), effective as of June 7, 2024 (the “Effective Date”) (this “Agreement”).
